| 1 |
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Robert John Motzer, Thomas E. Hutson, Piotr Tomczak et al. · New England Journal of Medicine
Open access |
10 Jan 2007 |
5,801 |
| 2 |
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al. · New England Journal of Medicine
Open access |
11 Sep 2017 |
5,453 |
| 3 |
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann Sebastian De Bono et al. · New England Journal of Medicine
Open access |
25 May 2011 |
4,448 |
| 4 |
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo et al. · New England Journal of Medicine
Open access |
4 Jun 2018 |
3,816 |
| 5 |
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
James Larkin et al. · New England Journal of Medicine
Open access |
28 Sep 2019 |
3,784 |
| 6 |
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al. · New England Journal of Medicine
Open access |
26 Feb 2020 |
3,298 |
| 7 |
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
Robert John Motzer, Bernard J. Escudier, Stéphane Marie. Oudard et al. · The Lancet
|
23 Jul 2008 |
3,036 |
| 8 |
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Leonard B. Saltz, John Vernon Cox, Charles David Blanke et al. · New England Journal of Medicine
Open access |
28 Sep 2000 |
3,022 |
| 9 |
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Jeffrey S. Weber et al. · New England Journal of Medicine
Open access |
10 Sep 2017 |
2,249 |
| 10 |
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
Lyndsay N. Harris, Herbert A. Fritsche, Robert Gary Mennel et al. · Journal of Clinical Oncology
|
22 Oct 2007 |
2,233 |
| 11 |
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer Keating Litton, Hope S. Rugo, Johannes Ettl et al. · New England Journal of Medicine
Open access |
15 Aug 2018 |
2,198 |
| 12 |
Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey Alan Sosman et al. · New England Journal of Medicine
Open access |
22 Feb 2012 |
2,170 |
| 13 |
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobágyi et al. · New England Journal of Medicine
Open access |
8 Oct 2016 |
2,066 |
| 14 |
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
Jeffrey D. Bradley et al. · The Lancet Oncology
Open access |
15 Jan 2015 |
2,047 |
| 15 |
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Robert John Motzer et al. · New England Journal of Medicine
Open access |
21 Aug 2013 |
1,936 |
| 16 |
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al. · New England Journal of Medicine
Open access |
Apr 2020 |
1,874 |
| 17 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I. Rini et al. · The Lancet
|
4 Nov 2011 |
1,861 |
| 18 |
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert John Motzer et al. · New England Journal of Medicine
Open access |
13 Feb 2021 |
1,811 |
| 19 |
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Aditya Bardia et al. · New England Journal of Medicine
Open access |
21 Apr 2021 |
1,671 |
| 20 |
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
M.C. Liu et al. · Annals of Oncology
Open access159 authors |
30 Mar 2020 |
1,567 |
| 21 |
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Frank Stephen Hodi, Vanna Chiarion‐Sileni, Rene C. Gonzalez et al. · The Lancet Oncology
|
22 Oct 2018 |
1,426 |
| 22 |
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott et al. · Nature Medicine
Open access |
29 May 2018 |
1,280 |
| 23 |
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
Robert H. Collins, Ofer Shpilberg, William R. Drobyski et al. · Journal of Clinical Oncology
|
Feb 1997 |
1,261 |
| 24 |
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
Toni K. Choueiri et al. · New England Journal of Medicine
Open access |
25 Sep 2015 |
1,248 |
| 25 |
Phase 3 trial of everolimus for metastatic renal cell carcinoma
Robert John Motzer, Bernard J. Escudier, Stéphane Marie. Oudard et al. · Cancer
|
14 Jun 2010 |
1,148 |
| 26 |
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
Jedd D. Wolchok et al. · Journal of Clinical Oncology
Open access |
24 Nov 2021 |
1,144 |
| 27 |
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
Javier Cortés, Joyce O’Shaughnessy, David M. Loesch et al. · The Lancet
|
Mar 2011 |
1,110 |
| 28 |
A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
Fadlo Raja Khuri, John J. Nemunaitis, Ian Ganly et al. · Nature Medicine
|
Aug 2000 |
1,109 |
| 29 |
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Bernard J. Escudier, Tim G Eisen, Walter Michael Stadler et al. · Journal of Clinical Oncology
Open access |
18 May 2009 |
1,089 |
| 30 |
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Fei Su et al. · New England Journal of Medicine
Open access |
18 Jan 2012 |
1,038 |
| 31 |
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Stephen R.D. Johnston et al. · Journal of Clinical Oncology
Open access |
20 Sep 2020 |
1,037 |
| 32 |
Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor−κB, and Up-regulating Expression of MicroRNA-21
Yongzhi Peter Yang, Wenhao Weng, Junjie Peng et al. · Gastroenterology
Open access |
19 Nov 2016 |
1,025 |
| 33 |
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours
David S. Hong et al. · British Journal of Cancer
Open access |
Apr 2020 |
974 |
| 34 |
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
Kimberly Blackwell, Harold J. Burstein, Anna Maria Storniolo et al. · Journal of Clinical Oncology
Open access |
2 Feb 2010 |
962 |
| 35 |
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Toni K. Choueiri et al. · The Lancet Oncology
Open access |
5 Jun 2016 |
957 |
| 36 |
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
Robert John Motzer, Thomas E. Hutson, Hilary Glen et al. · The Lancet Oncology
Open access |
25 Oct 2015 |
957 |
| 37 |
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
Martin Reck et al. · The Lancet Respiratory Medicine
|
26 Mar 2019 |
954 |
| 38 |
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
Michael J. Keating, Ian W. Flinn, Vinay Kumar Jain et al. · Blood
|
15 May 2002 |
951 |
| 39 |
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
Robert Louis Coleman et al. · New England Journal of Medicine
Open access |
28 Sep 2019 |
944 |
| 40 |
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
R. Charles Coombes et al. · The Lancet
|
Feb 2007 |
914 |
| 41 |
American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
Lowell E. Schnipper et al. · Journal of Clinical Oncology
Open access |
23 Jun 2015 |
913 |
| 42 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
Gabriel N. Hortobágyi et al. · Annals of Oncology
Open access |
25 Apr 2018 |
893 |
| 43 |
Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma
Lee S. Rosen, David Gordon, Mary Kaminski et al. · Cancer
Open access |
29 Aug 2003 |
877 |
| 44 |
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
Aditya Bardia, Ingrid A. Mayer, Linda T. Vahdat et al. · New England Journal of Medicine
|
20 Feb 2019 |
875 |
| 45 |
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
Jeffrey S. Weber et al. · The Lancet
|
21 Jan 2024 |
871 |
| 46 |
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
Joyce A O'Shaughnessy, Cynthia Osborne, John Pippen et al. · New England Journal of Medicine
|
5 Jan 2011 |
817 |
| 47 |
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
Sylvia Adams et al. · Annals of Oncology
Open access |
22 Nov 2018 |
810 |
| 48 |
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
David Cameron et al. · Breast Cancer Research and Treatment
|
10 Jan 2008 |
810 |
| 49 |
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
Toni K. Choueiri et al. · New England Journal of Medicine
Open access |
18 Aug 2021 |
792 |
| 50 |
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Sibylle Loibl, Joyce O’Shaughnessy, Michael Untch et al. · The Lancet Oncology
|
28 Feb 2018 |
781 |